Print page

White Papers

Title Author Date
How to Respond to (and Avoid) FDA 483s Veriteq, a Vaisala company 01/24/2011
 
Drug Safety: Improvement Needed in FDA’s Postmarket Decision-making and Oversight Process U.S. Government Accountability Office 04/24/2006
 
Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Food and Drug Administration 01/19/2006
 
FDA Guidance: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment U.S. Food and Drug Administration 03/26/2005
 
Influenza Vaccine: Current Status, Lessons Learned and Preparing for the Future U.S. Food and Drug Administration 02/18/2005
 
Guidance for Industry: Computerized Systems in Clinical Investigations U.S. FDA (CDER, CBER, CDRH) 05/10/2007
 
A Profile of the Pharmaceutical Manufacturing Industry U.S. Environmental Protection Agency 01/20/2006
 
[Report on] the Food and Drug Administration’s National Drug Code Directory U.S. Dept. of Health & Human Services' Office of Inspector General 08/15/2006
 
Kick–Starting PAT to Achieve Quality by Design in cGMP Bioprocessing TechniKrom, Inc. 10/02/2006
 
Software-Based Validation of Processing Systems Following 21 CFR 11 Siemens 04/29/2005
 
A Perspective on Standards: A Tool for Global Competitive Survival in an Increasingly Complex Regulatory World Rockwell Automation 02/22/2008
 
Applications Note on Multipurpose Peeler Centrifuges Riera Nadeu U.S.A. 04/29/2005
 
Unlocking the Power of Pharmacovigilance PriceWaterhouse Coopers 05/28/2007
 
Process Modeling and Control Challenges in the Pharmaceutical Industry Phil Dell'Orco, GlaxoSmithKline 02/24/2006
 
U.S.A. GMPs: What Offshore API Manufacturers Need to Know Nicholas Buhay, Deputy Director of Manufacturing and Product Quality, FDA's CDER 02/20/2006
 
21 CFR 11: Risks of Noncompliance Master Control 08/24/2005
 
Handling MSDSs and Global Hazard Communications Marshall Denhoff, American Industrial Hygienists Assn. 04/29/2005
 
Complimentary Reports: Pharmaceutical Domain Management and Protecting Pharmaceutical Brands MarkMonitor 10/08/2008
 
Accounting for Risk in Your Asset Management Strategy Life Cycle Engineering 09/23/2009
 
Compliance, Risk and Cost of Ownership Comparisons for Pharmaceutical Continuous Monitoring: Wired, Wireless and Standalone Monitoring Systems Ken Appel, Manager Regulated Markets, Veriteq, a Vaisala company 02/03/2011
 
Search Result: 1 - 20 of 45

Next 20